Navigation Links
Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
Date:3/15/2013

ROCKVILLE, Md., March 15, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical trial programs and reported its 2012 financial results for the year ended December 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO

"2012 saw the company achieve success in all of its Phase I clinical trial objectives," said Karl Johe , Ph.D., Neuralstem's Chairman of the Board and Chief Scientific Officer. "We have been able to demonstrate the safety and tolerability of Neuralstem's novel core technologies, from intraspinal transplantation procedures, to the cells themselves in ALS patients, as well as our NSI-189 neurogenic small molecule drug in healthy volunteers. Additionally, we believe we have seen evidence of a treatment effect in some NSI-566 cell therapy patients over a sustained period of time, as measured by levels of functional recovery and a slowdown in the progression of ALS. In spinal cord injury, a leading peer-reviewed scientific journal, 'CELL,' published compelling evidence that NSI-566 cells can 'bridge the gap' in a severed spinal cord animal model and return functionality. We have recently been approved by the FDA to commence a trial treating chronic spinal cord injury patients.

A highlight of 2012 was the completion of our ground-breaking ALS Phase I trial. Following the last treatment of the final cervical cohort of return patients in August, our collaborators, University of Michigan's Dr. Eva Feldman and Emory University's Dr. Jonathan Glass , presented trial data that showed promise of a treatment effect for ambulatory ALS patients as well as definitive DNA-fingerprint evidence of long-term NSI-566 cell survival," continued Dr. Johe. "These positive data support our plan to
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GenoSpace , a precision medicine software company that has developed ... of genomic, imaging and other biomedical data in research and ... , CEO of Aspera, an IBM Company, to its board ... "We are pleased to welcome Michelle ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... (Nasdaq: OREX ), a biopharmaceutical company focused on ... third quarter ended September 30,2010 on Wednesday, November 3, 2010 ... a live webcast and conference call at 5:00 p.m. Eastern ... and webcast to discuss financial results and recent business highlights. ...
... (Nasdaq: UTHR ) today announced its results of operations ... for the third quarter of 2010 were $171.0 million, up from ... the third quarter of 2010 was $39.7 million, or $0.70 per ... per basic share, for the same quarter in 2009. Gross margin ...
... the Human Genome -- REYKJAVIK, Iceland, October 27, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Biology Technology:United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 2United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 3United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 4United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 5United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 6United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 7The New deCODE Map of the Human Genome 2The New deCODE Map of the Human Genome 3The New deCODE Map of the Human Genome 4The New deCODE Map of the Human Genome 5The New deCODE Map of the Human Genome 6The New deCODE Map of the Human Genome 7The New deCODE Map of the Human Genome 8The New deCODE Map of the Human Genome 9
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 Based on ... Samsung introduces for the first time a fingerprint sensor ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
(Date:12/15/2014)... Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced the ... report to their offering. ... technology used for the identification of individuals. Facial recognition ... such as nose, jaw edges, mouth, and the distance ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... A team led by a scientist at The Scripps Research ... the National Institutes of Health to uncover the workings of ... NIH since 2002. The grant is focused on innovative ... range of human diseases that include viral and bacterial infections ...
... Medicine and Hygiene,s two prestigious journals will join the Oxford ... the organizations. The journals, Transactions of the ... International Health , seek to promote and advance the study, ... in the tropics and sub-tropics. The Society plays a ...
... TREW Marketing today announced it is now certified ... the HubSpot platform, TREW can help science, engineering, and ... consistent flow of qualified leads that fuel new sales ... clients stay on the leading edge of marketing best ...
Cached Biology News:Team receives $22.5 million to shed light on the immune system 2Prestigious Royal Society of Tropical Medicine and Hygiene journals join Oxford University Press 2HubSpot Certifies TREW Marketing for Integrated Marketing Platform 2HubSpot Certifies TREW Marketing for Integrated Marketing Platform 3
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
... Fluorescein Direct In Situ Apoptosis ... in situ by the direct ... are tagged with a directly ... provides fluorescence staining for 40 ...
... is a two color staining method ... DNA to detect apoptotic cells by flow ... and reagents required for measuring apoptosis in ... for assessing reagent performance; washing, reaction, and ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
Biology Products: